AUA2024: Incorporating Genomic Testing and Advanced Imaging For Prostate Cancer Into Your Practice

Incorporating Genomic Testing and Advanced Imaging For Prostate Cancer Into Your Practice CME Available: https://auau.auanet.org/node/41033 At the conclusion of this activity, participants will be able to: 1. Identify the research that led to the approval of genomic cancer for prostate cancer and the implementation of advanced imaging for prostate cancer. 2. Order appropriate genomic testing and advanced imaging based on a patient's unique clinical situation. 3. State the National Comprehensive Cancer Network Guidelines for genomic testing and advanced imaging for prostate cancer. 4. Discern the different prognostic end points provided by various genomic tests. 5. Recognize candidates for, and implications of, germline testing for prostate cancer. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.

There are no comments yet.

Please log in to write the first comment.